Shopping Cart

You have 0 items in your cart
    You are currently here:

    Mouse Anti-Human TIE-2-FITC

    Size:
    50 µg
    Price:
    € 230
    Formulation:
    Monoclonal Antibody ; liquid
    Clone/AB feature:
    (#tek16)
    Isotype:
    IgG1
    Label:
    FITC
    Catalog Number:
    101-M54-FITC
    Synonyms:
    TEK; TIE2; VMCM; TIE-2; VMCM1; CD202B; FITC
    Application:
    FC
    Antibody generation:
    The monoclonal antibody was produced with the help of BALB/c mice using recombinant human soluble extracellular TIE-2 as the immunizing antigen. Mouse IgG1 antibody (#tek16) from hybridomas was purified from cell culture supernatant by Protein G chromatography and then biotinylated using a standard protocol. The unconjugated antibody will detect native human TIE-2/tek in ELISA experiments and on the surface of different human cell types.
    Antigen:
    recombinant human soluble extracellular TIE-3
    Stability:
    Store protected from light at 2-8°C. DO NOT FREEZE!
    Description:
    Tie-1/Tie and Tie-2/Tek are receptor tyrosine kinases with unique structural characteristics including two immunoglobulin-like domains flanking three epidermal growth factor (EGF)-like domains, followed by three fibronectin type III-like repeats in the extracellular region, and a split tyrosine kinase domain in the cytoplasmic region. Tie-2 is involved in vascular stabilization and remodeling. Although less well understood, Tie-1 may also act as an ANG receptor, possibly in complex with Tie-2. Human Tie-2 cDNA encodes a 1124 amino acid (aa) residue precursor protein with an 18 residue putative signal peptide, a 727 residue extracellular domain and a 354 residue cytoplasmic domain. Tie-2 is a receptor for the angiopoietin (ANG) family: ANG-1, ANG-2, and ANG-3 (mouse)/-4 (human). Ang-2 has been reported to act as an antagonist for Ang-1. Mice engineered to overexpress Ang-2 or to lack Ang-1 or Tie-2 display similar angiogenesis defects.
    NCBI Gene ID:
    7010
    Uniprot:
    Q02763
    References:
    Chin et al. Anticancer Res. 24:2353, 2004; Scheufler et al., J Cereb Blood Flow Metab. 23:99, 2003; Reusch et al., Angiogenesis 4:123, 2001; Harris et al., Clin Cancer Res. 7 :1992, 2001
    PDF Download: